logo-loader
Amryt Pharma PLC

Fastnet Oil & Gas expands Celtic Sea footprint

oil_rig_platform_350_5513b2ede461d.jpg

Fastnet Oil & Gas (LON:FAST) has expanded its footprint in the Celtic Sea, off Ireland’s south coast.

The company told investors it has been awarded new acreage, namely the Ventry licensing option, which spans 996 square kilometres, contiguous with its Mizzen and East Mizzen options.

It now has 18 months, initially, to reprocess existing 2D seismic data and carry out geological studies.

At the same time Fastnet has been granted extensions for the East Mizzen and Shanagarry acreage, where it also now has 18 months to complete similar work commitments.

The company has also extended the timeline for its option with Petronas unit PSE Kinsale Energy over the Deep Kinsale project until the end of December 2015. It allows ongoing farm-out talks to continue.

Carol Law, Fastnet’s chief executive, said these new arrangements for the Celtic Sea portfolio reflect the successful and significant investment of the group’s time, expertise and resources.

She describes it as a portfolio of attractive and low risk projects, with excellent project economics even in the current oil pricing environment.

“We are delighted to add the Ventry Licensing Option to our portfolio, and believe it offers significant extension acreage with potential material upside on the west side of the large Mizzen structural prospect,” Law said.

“We believe the western side of this large uplift will contain similar prospective stratigraphic features to those mapped on our 2013 3D seismic on the eastern flank of the Mizzen high and, in the event of exploration success in Mizzen and East Mizzen, we will be well positioned with running room on the plays.”

Quick facts: Amryt Pharma PLC

Price: £0.12

Market: AIM
Market Cap: £5.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

2 min read